E. E. Blokhova

E. E. Blokhova

Auto-generated profile, based on publicly available information

E. E. Blokhova

Ryazan State Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Problems of Nutrition
Verified
Journal Article
Closed access
RURyazan State Medical University
Ryazan State Medical University
NBN.A. Belykh
N.A. Belykh
EBE.E. Blokhova
E.E. Blokhova
Обеспеченность витамином D и показатели кальций-фосфорного обмена у детей с избыточном массой тела и ожирением

30 September 2019 in Nauka Molodykh (Eruditio Juvenium)
Verified
Journal Article
Open access
RURyazan State Medical University
Ryazan State Medical University
NBN.A. Belykh
N.A. Belykh
EBE.E. Blokhova
E.E. Blokhova

1 January 2021 in Problems of Nutrition
Verified
Journal Article
Closed access
NBN.A. Belykh
N.A. Belykh
RFRyazan State Medical University named after academician I.P. Pavlov of the Ministry of Healthcare of the Russian Federation
Ryazan State Medical University named after academician I.P. Pavlov of the Ministry of Healthcare of the Russian Federation
EBE.E. Blokhova
E.E. Blokhova
ILI.N. Lebedeva
I.N. Lebedeva
ANA.A. Nikiforov
A.A. Nikiforov
RDRyazan Regional Children’s Clinical Hospital Named After N.V. Dmitrieva
Ryazan Regional Children’s Clinical Hospital Named After N.V. Dmitrieva
Overweight children represent a particularly vulnerable group for hypovitaminosis D. Clinical studies on the relationship between vitamin D (VD) deficiency and metabolic risk factors for cardiovascular disorders are controversial, and for children of primary school age who have overweight and obesity are insufficient. The aim of the research was to study the relationship between lipid and carbohydrate metabolism indicators and VD status in children, depending on the body mass index. Material and methods. A cross-sectional (one-step) study was carried out on a sample of 154 children with different weight of 8-10 years old (74 girls, 80 boys). Three groups of research participants were identified: group 1 - 44 obese, group 2 - 58 overweight, group 3 - 52 children with normal body weight. For all children, the serum level of 25(OH)D, parathyroid hormone (PTH), calcium (Ca), phosphorus (P), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), ß-lipoproteins, glucose, insulin was determined, and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was also calculated. Results. VD deficiency in obese children was found almost 2.3 fold more often than in overweight (p=0.002) and 2.8 fold more often than in children with normal body weight (p=0.001). Indicators of lipid and carbohydrate metabolism were within physiological limits. However, in obese children they significantly exceeded the indicator of healthy children (p<0.05). When comparing the results of biochemical studies, it was revealed that children with VD deficiency [25(OH)D <20 ng/ml] had statistically significantly higher medians of PTH, TC, TG, ALT, AST, glucose, insulin, HOMA-IR and lower P and Ca level compared with children with normal micronutrient blood content (p<0.05). The medians of ALT, AST, TC, ß-lipoproteins, TG, glucose, insulin and HOMA-IR levels in obese children with VD deficiency were statistically significantly higher than in children with normal body weight and VD deficiency and in healthy children with an optimal concentration of 25(OH)D. At the same time, there was no statistically significant difference between the indicators of lipid and carbohydrate metabolism in the group of healthy children with normal VD status and its deficiency. Conclusion. VD deficiency is an important predictor of obesity complications and it exacerbates the risk of cardiometabolic disorders in children who are obese in the early school years.

3 November 2023 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
NBN.A. Belykh
N.A. Belykh
EBE.E. Blokhova
E.E. Blokhova
Дети с избыточной массой тела представляют собой особо уязвимую группу по гиповитаминозу D. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить взаимосвязь показателей липидного и углеводного обмена с обеспеченностью витамином D (VD) детей препубертатного возраста с избыточной массой тела и ожирением. МАТЕРИАЛ И МЕТОДЫ В поперечное (одномоментное) исследование были включены 77 детей в возрасте от 8 до 10 лет, которые в зависимости от индекса массы тела были разделены на три группы: 1-я группа — 26 детей с нормальной массой тела; 2-я группа — 29 детей с избыточной массой тела; 3-я группа — 22 ребенка с ожирением. VD-статус оценивали по уровню 25(ОН)D в сыворотке крови, липидный и углеводный обмен — по концентрации аланинаминотрансферазы (АЛТ) и аспартатаминотрансферазы (АСТ), общего холестерина (ХС), β-липопротеинов, триглицеридов (ТГ), глюкозы, инсулина с расчетом индекса инсулинорезистентности HOMA-IR. РЕЗУЛЬТАТЫ Дефицит VD у детей с ожирением регистрировали в 2,3 раза чаще, чем при избыточной массе тела (p=0,002), и в 2,8 раза чаще, чем у здоровых детей (p=0,001). В 1-й группе показатели липидного и углеводного обмена статистически значимо превышали таковые у здоровых детей (p<0,05). На фоне дефицита VD у детей имели место более высокие концентрации ХС, ТГ, АЛТ, АСТ, глюкозы, инсулина, значения НОМА-IR по сравнению со сверстниками, имеющими нормальное содержание 25(ОН)D (p<0,05). Показатели липидного профиля и углеводного обмена у детей с ожирением и дефицитом VD статистически значимо превышали значения у сверстников с нормальной массой тела, имеющих дефицит VD, и у здоровых детей с оптимальным VD-статусом. При этом отсутствовала статистически значимая разница между показателями липидного и углеводного обмена в группе здоровых детей с нормальным VD-статусом и гиповитаминозом D. ЗАКЛЮЧЕНИЕ Дефицит витамина D является важным предиктором формирования инсулинорезистентности и нарушений липидного обмена у детей с ожирением уже в препубертатном возрасте.

22 October 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
RGR. A. Gudkov
R. A. Gudkov
ADA. V. Dmitriev
A. V. Dmitriev
NFN. V. Fedina
N. V. Fedina
VPV. I. Petrova
V. I. Petrova
EBE. E. Blokhova
E. E. Blokhova
MTM. R. Terzieva
M. R. Terzieva
Progressive familial intrahepatic cholestasis is one of the causes of direct hyperbilirubinemia in young children and the need for its diagnosis arises after the exclusion of such more common causes of cholestasis as biliary atresia, Alajille syndrome, as well as infectious and medicinal hepatopathies. The basic diagnostic feature that allows us to suspect the pathology in question is the absence of an increase in the level of γ-glutamine trans peptidase. To date, 12 types of progressive familial intrahepatic cholestasis have been described. For most of them, both severe cases with neonatal manifestation and rapid progression to cirrhosis, as well as variants with late development and a relatively benign course, are described. The article presents brief genetic and phenotypic characteristics of all 12 types of pathology. The author presents his own observation of a patient whose clinical and laboratory picture corresponded to Byler’s syndrome, but the identified genetic characteristics did not correspond to any of the known types.

5 April 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
RGR. A. Gudkov
R. A. Gudkov
EBE. E. Blokhova
E. E. Blokhova
ADA. V. Dmitriev
A. V. Dmitriev
AZA. L. Zaplatnikov
A. L. Zaplatnikov
Drug fever is a febrile reaction that coincides in time with and is pathogenetically associated with the use of a drug. The review presents publications of epidemiological and clinical studies on various variants of fever development due to the use of pharmacological agents. Febrile reactions associated with both immune hypersensitivity and those with other mechanisms of development, as well as drug hypersensitivity syndromes, including fever as one of the syndromes (drug-induced hypersensitivity syndrome, serum sickness, drug-induced lupus), are considered. Most often, the term “drug fever” is used to define cases with isolated febrile increase in body temperature, not accompanied by other clinical symptoms (for example, rash or organ damage), and having an immune genesis. An association of drug fever with an extremely wide range of drugs has been established, but most often it is caused by beta-lactam antibiotics. There is a high probability of drug fever in intensive care unit patients who have a high risk of bacterial infection and receive long courses of antibiotics. Underdiagnosis of drug fever leads to unjustified continuation and intensification of antibacterial therapy, increased risk of iatrogenic complications and economic costs. The review also presents variants of drug hyperthermia: malignant neuroleptic syndrome, malignant hyperthermia, serotonin syndrome, propofol infusion syndrome and some others. Despite the long history of studying the issue, the pathogenesis of the pathology remains not entirely clear, there are no specific diagnostic markers and the diagnosis is still made by exclusion.